Molecular super enhancers: A new key for targeted therapy of brain cancer in children

December 20, 2017, German Cancer Research Center

Ependymoma refers to a heterogeneous group of cancers that can occur at any age, and is one of the most common types of brain cancer in children. The genetic causes for its development are largely unknown and there are no targeted treatments to date. Scientists from the Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), in collaboration with colleagues from the U.S. and Canada, have now developed a molecular approach that opens new treatment prospects.

Targeted therapies in cancer medicine are often based on genome sequencing—a technique that makes it possible to identify targets for precision drugs. However, in some cancer types, these structures have not been found to date. This includes ependymoma, a group of brain tumors that are considered to be largely resistant to chemotherapy. Therefore, it would be crucial to find new options for treating them. Ependymoma can affect children as well as adults. In children, it is one of the most frequent types of .

In the quest for novel therapeutic approaches in the treatment of ependymoma, the scientists have now taken a circuitous route. Testing an alternative approach, they took a closer look at so-called enhancers, regions of the genome that regulate the activity of genes, for example, by serving as docking sites for regulatory proteins (transcription factors). Groups of enhancers with strong enhancer potential for key cellular processes are also called super-enhancers. These have already been linked to tumor development in other .

"Using various genetic and epigenetic analysis methods to examine 42 ependymoma samples, we were able to identify almost 1700 super-enhancers and assign them to specific molecular groups of ependymoma," said Marcel Kool, who is a at the Pediatric Neurooncology Division of the German Cancer Research Center (DKFZ) and also works at the KiTZ. "We subsequently demonstrated that many of these super-enhancers influence the activity of genes that are implicated in the development of ."

The researchers then took a closer look at the 15 most frequent super-enhancers. They were able to demonstrate that these enhancer elements regulate molecules that are involved in key cellular processes and may therefore be used as targets for targeted therapies. "We have thus identified whole new regulatory circuits controlling tumors development in ependymoma. We were able to interrupt these regulatory circuits using specific agents. As a result, the ependymoma cells slowed down their growth and finally died," said Kristian Pajtler, who is a group leader at DKFZ's Pediatric Neurooncology Division and a scientist at the KiTZ.

Stefan Pfister, DKFZ department head and senior physician at Heidelberg University Hospital, says, "The research results open prospects of completely new treatment options for children with , a group of tumors for which we have lacked good drug-based approaches so far."

Explore further: Brain tumors found to have a two-tier system

More information: Stephen C. Mack et al, Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling, Nature (2017). DOI: 10.1038/nature25169

Related Stories

Brain tumors found to have a two-tier system

August 23, 2011
Ependymomas are the second most frequent type of malignant brain tumor in children. Ependymoma develops from precursor cells of the tissue that lines the hollow cavities of the brain. Therapy results of ependymoma vary immensely: ...

First roadmap of stomach cancer super-enhancers paves the way for new treatments

July 26, 2017
A*STAR researchers have homed in on a potential new way to diagnose and treat stomach cancer, through the mapping of an unprecedented catalog of almost 3,800 super-enhancers from stomach cancer tumor cells.

Scientists identify childhood brain cancer genes

September 15, 2008
Scientists at The University of Nottingham have isolated three important genes involved in the development of a type of childhood brain cancer. The breakthrough is revealed in a study published in the British Journal of Cancer ...

Researchers mine the epigenome to identify likely origins of childhood brain tumor subtype

January 27, 2016
Researchers have identified the cells that likely give rise to the brain tumor subtype Group 4 medulloblastoma. The finding removes a barrier to developing more effective targeted therapies against the brain tumor's most ...

Promising target for treating brain tumors in children

November 28, 2017
Findings published in Oncotarget offer new hope for children with highly aggressive brain tumors like atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma. Previously, the authors of the study have shown that an experimental ...

New strategy likely to speed drug development for rare cancers

September 15, 2011
Researchers have identified promising new therapies for ependymoma, a rare tumor with few treatment options. St. Jude Children's Research Hospital investigators led the effort, which used a new, faster drug development system ...

Recommended for you

A code for reprogramming immune sentinels

December 10, 2018
For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells. The process is quick and effective, representing a pioneering ...

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Major breakthrough in quest for cancer vaccine

December 6, 2018
The idea of a cancer vaccine is something researchers have been working on for over 50 years, but until recently they were never able to prove exactly how such a vaccine would work.

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Scientists develop new technology for profiling unique genetic makeup of myeloma tumor cells

December 6, 2018
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells—outlining how cancer cells hijack specific pathways for uncontrolled proliferation—will lead to more efficient ways to fight it. Joint ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.